Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | SPNS2 | Q8IVW8 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28567227 | 0.82 | NPC1 (0.62) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL28591483 | 0.79 | NPC1 (0.81) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL28563611 | 0.78 | NPC1 (0.57) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL5050408 | 0.77 | NPC1 (0.67) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL29966218 | 0.77 | L3MBTL1 (0.54) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL4551880 | 0.77 | MEN1 (0.65) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL18356776 | 0.76 | NPC1 (0.64) | NPC1RAB9AATML3MBTL1MEN1 | |
| SCHEMBL9991081 | 0.76 | HDAC8 (0.60) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL5051923 | 0.75 | HDAC3 (0.64) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL28231668 | 0.75 | TLR8 (0.53) | NPC1RAB9AATML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | NPC1 176/4885RAB9A 531/4885ATM 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.